Updated on: Jan 9 2014

Scientific Projects



Multiple Myeloma (MM) is an orphan and rare plasma cell malignancy with an incidence rate of 5.7/100,000 people in the European Union (EU), and 27,500 new cases reported each year. The median age at diagnosis is 70 years.

The clinical course of MM is markedly heterogeneous in both response to therapy and survival: some patients die from disease evolution within few months, whereas others live for over 10 years. The International Staging System (ISS), the presence of chromosomal abnormalities, and the archievement of complete response (CR) are traditionally used to identify patients with good or poor prognosis. Genomic and cytomic technologies provide novel, simple and powerful molecular-based prognostic and predictive tools. The validation of these later technologies and biomarkers will enable physicians to identify individual tailored therapies.
Sex, age, comorbidities and disabilities are still significantly affecting outcome. When compared with fit patients with similar disease-related features, outcome is inferior in patients with co-morbid conditions.

Such questions in this rare disease can only be answered by large randomised clinical trials and coordinated activities as proposed in this project. This is possible now, thanks to a number of excellent research groups that have been established throughout Europe. There has been a lack of coordinated activities, avoiding major clinical development or breakthrough.
The TALISMMAN project offers a unique opportunity to involve the key players to challenge actual standard therapies and develop tailored strategies.

The TALISMMAN consortium congregates the necessary competence and critical mass in terms of expertise and resources to ensure the achievement of the Project goals. The participation of worldwide recognised experts in multiple myeloma, molecular biology and biostatistics who belong to the European Myeloma Network (EMN) guarantees the success of the approach proposed and the presence of European Myeloma Platform (EMP) as a partner, is crucial to guarantee that the results reach patients and really change clinical practice. Finally, the participation of the private sector will bring the industrial perspective to the Consortium and consequently, they will increase the expected impact of the Project outcomes.

Secr. Hans E. Johnsen | Depart. of Haematology | Aalborg University Hospital | Sdr. Skovvej 15 | DK-9000 Aalborg | Denmark | T:+45 9766 3871 | F:+45 9766 6369